| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bristol-Myers Squibb Company (MX: BMY)
BMY Technical Analysis
5
| As on 9th Jun 2023 BMY STOCK Price closed @ 1128.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1398.52 & Strong Sell for SHORT-TERM with Stoploss of 1223.72 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BMYSTOCK Price
| Open | 1128.00 | Change | Price | % |
| High | 1128.00 | 1 Day | -1.00 | -0.09 |
| Low | 1128.00 | 1 Week | -19.00 | -1.66 |
| Close | 1128.00 | 1 Month | -119.03 | -9.55 |
| Volume | 481 | 1 Year | -39.98 | -3.42 |
| 52 Week High 1600.00 | 52 Week Low 1116.00 | ||||
MX Mexico Most Active Stocks
| AMXL | 19.28 | -0.36% |
| CEMEXCPO | 12.06 | 0.58% |
| GIGANTE | 19.67 | -6.11% |
| HCITY | 7.78 | 3.73% |
| WALMEX | 67.47 | -1.10% |
| FR | 439.66 | 0.34% |
| KIMBERA | 38.43 | 0.63% |
| GFNORTEO | 140.87 | 0.90% |
| FUNO11 | 25.73 | 0.74% |
| GMEXICOB | 85.38 | 1.51% |
MX Mexico Top Gainers Stocks
MX Mexico Top Losers Stocks
| BMY Daily Charts |
BMY Intraday Charts |
Whats New @ Bazaartrend |
BMY Free Analysis |
|
|
BMY Important Levels Intraday
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
| RESISTANCE | 1128.00 |
BMY Forecast May 2024
| 4th UP Forecast | 1465.21 |
| 3rd UP Forecast | 1357.06 |
| 2nd UP Forecast | 1290.22 |
| 1st UP Forecast | 1223.37 |
| 1st DOWN Forecast | 1032.63 |
| 2nd DOWN Forecast | 965.78 |
| 3rd DOWN Forecast | 898.94 |
| 4th DOWN Forecast | 790.79 |
BMY Weekly Forecast
| 4th UP Forecast | 1309.85 |
| 3rd UP Forecast | 1251.53 |
| 2nd UP Forecast | 1215.48 |
| 1st UP Forecast | 1179.43 |
| 1st DOWN Forecast | 1076.57 |
| 2nd DOWN Forecast | 1040.52 |
| 3rd DOWN Forecast | 1004.47 |
| 4th DOWN Forecast | 946.15 |
BMY Forecast2024
| 4th UP Forecast | 2097.28 |
| 3rd UP Forecast | 1786.43 |
| 2nd UP Forecast | 1594.28 |
| 1st UP Forecast | 1402.14 |
| 1st DOWN Forecast | 853.87 |
| 2nd DOWN Forecast | 661.72 |
| 3rd DOWN Forecast | 469.57 |
| 4th DOWN Forecast | 158.72 |
Bristol-Myers Squibb Company ( MX Mexico Symbol : BMY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BMY Business Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Address: 430 East 29th Street, New York, NY, United States, 10016
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service